Ten News Live

Amplus Solar Gets National Excellence Award from Government of India for Rooftop Project Development

Business Wire India

Amplus Energy Solutions Private Limited (“Amplus”), a portfolio company of I Squared Capital and one of India’s leading solar developers, has been selected for the National Award for Rooftop Project Developers by the Ministry of New and Renewable Energy (MNRE). The award was presented as part of the first ever National Workshop on Rooftop Solar in India, organised by MNRE.


Sanjeev Aggarwal, Managing Director and CEO, Amplus, said, “We are delighted that the Government of India has recognized Amplus Solar as National leader in the distributed solar generation segment. Amplus provides best-in-class solar facilities under a PPA model, reducing technology and investment risk commercial and industrial customers across Asia.”


Guru Inder Singh, Chief Operating Officer, Amplus added, “Amplus Solar has grown rapidly since the equity investment by I Squared Capital in June 2015. The company now has nation-wide capabilities providing project delivery, operations and maintenance to our customers. We continue to develop our rooftop portfolio and evaluate acquisitions in India and Asia. Amplus prides itself on the quality of its plants and the service provided through its remote monitoring center in Gurgaon and in-house SCADA system, which maximizes uptime for distributed generation and rooftop systems in Indian operating conditions.”


Amplus has recently partnered with Walmart to provide solar power at 15 Best Price Modern Wholesale stores across five states. In April 2016, Amplus commissioned India’s largest single-location rooftop solar installation for captive use of 4,000 kilowatts for Yamaha Motors.


The rooftop segment is expected to grow rapidly from a current capacity of around 525 megawatts to the Indian government’s target of 40,000 megawatts by 2022. Distributed solar has inherent advantages including speedy implementation, no transmission losses and use of “idle spaces,” like factory sheds and building terraces, making it ideal for generating renewable energy, especially in markets like India where land is at a premium.


About Amplus Energy Solutions Pvt. Ltd.


Amplus Energy Solutions is a leader in providing distributed solar and energy solutions to industrial and commercial customers in India. Amplus owns and manages a portfolio of operational and under-construction plants totaling more than 30,000 kilowatts, serving more than 25 customers at over 200 locations under its brand Amplus Solar and M+ Solar. Amplus is a portfolio company of I Squared Capital, a global private equity fund focused on developing long-term sustainable infrastructure assets globally. Amplus employs more than 70 people with offices in five major cities across India and has one of the largest specialised team of experienced professionals for the rooftop and distributed generation segment.


For Further details about the Amplus Group, please contact Sanjeev Aggarwal, sanjeev.aggarwal@amplussolar.com, +91 98715 16999. For new business enquiries or for installing solar power at your location, contact go.green@amplussolar.com or 1800-3070-8080.



Holostik Showcases its Innovative Anti-counterfeiting Solutions at Drupa 2016

Business Wire India
Holostik, the largest manufacturer of Security Holograms in the world is participating at Drupa 2016 taking place in Dusseldorf, Germany to showcase its futuristic technology such as latest applications, products in the Anti-Counterfeiting space.

Drupa – world's largest trade fair for the printing and print media industry that happens once in every four years. It brings together the global suppliers of print and print media industry including international exhibitors, products and services in the areas of media pre-press, printing machines, bookbinding, paper processing and Druckaterial. Drupa gives an insight into the latest developments, trends, services and products from the different areas in the sector.

This year Holostik is presenting its wide range of product portfolio including Security Holograms, Tax Stamps, Hot Stamping Foil, Shrink Sleeve, Wads Labels, Pouches etc. All these products are a result of Holostik’s concerted efforts towards Research & Development, in respect, to create solutions that protect the brand and ensure that the right product is a part of supply chain.

Speaking on the on the participation, U.K. Gupta, CMD at Holostik India Limited, “As per a recent research report, Counterfeiting costs more than 2% of total global economic output which adds up to around $1.8 trillion per year. Hence the world requires a call to action to fight the problem of counterfeiting. At Holostik, we have created innovative applications and products in the anti-counterfeiting space so as to bring authentic products to the end consumer, thereby, making the difference on a macro level. All such products will be on display at Drupa 2016.”

Holostik is showcasing at stall number E16 in Hall No. 3 at Drupa 3016 in Dusseldorf, Germany. Drupa will take place till June 10, 2016.
About Holostik:

Built with the DNA of innovation and technology, Holostik® has set milestones by being the largest manufacturer of security holograms in the world to today being an integrated IT enabled authentication solutions provider selling in 75+ countries. In the last 25 years of its existence, from being the undisputed leader in India, to being the largest exporter in anti-counterfeiting solutions; Holostik has always been the perfect brand's authentication partner. Holostik is one of the trusted and leading names in the Authentication Solution Provider of Holograms and holographic products in India.

World Environment Day Celebration at JNPT

Business Wire India
The World Environment Day was celebrated at JNPT, on the occasion, the Chairman Shri Anil Diggikar addressed the gathering, where he emphasise the importance of WED and JNPT’s initiatives to make the Port as green Port and ensure sustainable development. Also seminar and interactive session was held on the environment legal aspects on port and coast. Shri Sanjay Upadhyay, Advocate, Supreme Court and environment expert explained various provisions on environmental issues.

The programme was attended by the Shri Naresh Kumar, Chief Manager (Admin.) & Secy. Shri A.K. Bose, Chief Manager (Traffic), Sr. officers and Terminal Operators.

Photo Caption: Shri Anil Diggikar, IAS, Chairman, JNPT, Shri Sanjay Upadhyay, Advocate Supreme Court & Environment Expert and other officials on the occasion of ‘World Environment Day’

South India’s Biggest Culinary and Mixology Competition with U.S. Premium Agricultural Products Held in Bengaluru During Food Hospitality World

Business Wire India
To showcase the most delectable variety of fruits and nuts from America, U.S. Premium Agricultural Products will have a prominent presence at the upcoming Food Hospitality World (FHW), Bengaluru show from 9th-11th June at the White Orchid Convention Center, Bengaluru.

The event will host South India’s biggest Culinary and Mixology Competition to highlight the usage and versatility of premium products like U.S. Cranberries, Washington Apples, USA Pears, California Walnuts and U.S. Pecans as the main ingredient. This will be organized as a special event in concurrence with the “South India Culinary Challenge & Baking Contest” and “Mixology Challenge” in association with the South India Culinary Association (SICA). The competition will feature star hotel chefs and mixologists showcasing their exemplary skills. The contest will be judged in collaboration with SICA, reputed industry members and USDA representatives.

Talking about the initiative, Mr. Keith Sunderlal, India representative, U.S Cranberry Marketing Committee, said: “We are thrilled to be associated with one of India’s largest professional trade shows in the food and hospitality industry. Our objective for the campaign is to expand awareness and knowledge of the availability, versatility and utilization techniques of U.S. Cranberries, Washington Apples, USA Pears, California Walnuts, and U.S. Pecans in India. Through participation in FHW, the idea is to reach out to the trade and introduce them to the freshness, versatility and taste of U.S. premium agricultural products. Looking at the show’s past success, we are confident that we will be able to strike the right chord with our target audience."
To indulge in the premium agricultural products from USA, get set for Food Hospitality World!

About The Cranberry Marketing Committee (CMC):

The Cranberry Marketing Committee (CMC) USA is focused on promoting the use and consumption of cranberries worldwide. The CMC was established as a Federal Marketing Order in 1962 to ensure a stable, orderly supply of good quality product. The Marketing Order has been amended several times since its inception to further the CMC's ability to expand market development projects in domestic and international markets. Currently, CMC conducts generic promotion activities in the United States, China, India, Mexico, Pan-Europe and South Korea.

About Food Hospitality World

FHW is one of India’s largest professional trade show for trade & consumers in the food & hospitality industry. FHW is organized by two of the world’s biggest trade show organizers Deutsche Messe and Fiera Milano (HMFI) along with one of India’s largest publication house The Indian Express Limited. Previous year, the show witnessed 6,000 visitors, more than 250 exhibiting brands, more than 550 B2B meetings, more than 250 special event attendees.

About The SCS Group:

The SCS Agribusiness Consultants Pvt. Limited (referred to as THE SCS GROUP) is an agribusiness-consulting firm based in India providing services in the disciplines of marketing, logistics, strategy, policy, communications and training. The firm was established in 1998 with the conviction that the highly competitive global agricultural products' trade scenario demands in-depth research, sophisticated marketing strategies and meticulous implementation.

MSCI to Announce 2016 Market Classification Review

Business Wire India

MSCI Inc. (NYSE:MSCI) will be releasing the results of its Annual Market Classification Review on June 14, 2016. The announcement will be posted shortly after 5:00 pm Eastern Daylight Time/11:00 pm Central European Summer Time (CEST) at https://www.msci.com/market-classification.


After posting the review announcement, MSCI will hold two press conference calls in English, hosted by Remy Briand, Global Head of Research, to answer questions from the media. Note that these press conference calls are restricted to journalists.


First Conference Call

Date: Tuesday, June 14, 2016
Time: 1:00am CEST/12:00am BST/7:00pm EDT/7:00am CST
Toll Free Numbers:    
US: 866‐803‐2143   Hong Kong: 800‐900‐592
UK: 0800‐279‐3953   Japan: 00531‐12‐1857
China A: 10800-712-1320   China B: 10800-120-1320
S. Korea: 00798‐14800‐6732   Taiwan: 00801‐137‐708
UAE: 8000-35702379   Peru: 0800-53744
Participant passcode: MSCI    

Second Conference Call

Date: Wednesday, June 15, 2016
Time: 9:00am CEST/8:00am BST/3:00am EDT/3:00pm CST
Toll Free Numbers:    
US: 866‐803‐2143   Hong Kong: 800‐900‐592
UK: 0800‐279‐3953   Japan: 00531‐12‐1857
China A: 10800-712-1320   China B: 10800-120-1320
S. Korea: 00798‐14800‐6732   Taiwan: 00801‐137‐708
UAE: 8000-35702379   Peru: 0800-53744
Participant passcode: MSCI    

About MSCI


For more than 40 years, MSCI’s research-based indexes and analytics have helped the world’s leading investors build and manage better portfolios. Clients rely on our offerings for deeper insights into the drivers of performance and risk in their portfolios, broad asset class coverage and innovative research. Our line of products and services includes indexes, analytical models, data, real estate benchmarks and ESG research.


MSCI serves 97 of the top 100 largest money managers, according to the most recent P&I ranking. For more information, visit us at www.msci.com.


This document and all of the information contained in it, including without limitation all text, data, graphs, charts (collectively, the “Information”) is the property of MSCI Inc. or its subsidiaries (collectively, “MSCI”), or MSCI’s licensors, direct or indirect suppliers or any third party involved in making or compiling any Information (collectively, with MSCI, the “Information Providers”) and is provided for informational purposes only. The Information may not be modified, reverse-engineered, reproduced or redisseminated in whole or in part without prior written permission from MSCI.


The Information may not be used to create derivative works or to verify or correct other data or information. For example (but without limitation), the Information may not be used to create indexes, databases, risk models, analytics, software, or in connection with the issuing, offering, sponsoring, managing or marketing of any securities, portfolios, financial products or other investment vehicles utilizing or based on, linked to, tracking or otherwise derived from the Information or any other MSCI data, information, products or services.




Without limiting any of the foregoing and to the maximum extent permitted by applicable law, in no event shall any Information Provider have any liability regarding any of the Information for any direct, indirect, special, punitive, consequential (including lost profits) or any other damages even if notified of the possibility of such damages. The foregoing shall not exclude or limit any liability that may not by applicable law be excluded or limited, including without limitation (as applicable), any liability for death or personal injury to the extent that such injury results from the negligence or willful default of itself, its servants, agents or sub-contractors.


Information containing any historical information, data or analysis should not be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. Past performance does not guarantee future results.


The Information should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. All Information is impersonal and not tailored to the needs of any person, entity or group of persons.


None of the Information constitutes an offer to sell (or a solicitation of an offer to buy), any security, financial product or other investment vehicle or any trading strategy.


It is not possible to invest directly in an index. Exposure to an asset class or trading strategy or other category represented by an index is only available through third party investable instruments (if any) based on that index. MSCI does not issue, sponsor, endorse, market, offer, review or otherwise express any opinion regarding any fund, ETF, derivative or other security, investment, financial product or trading strategy that is based on, linked to or seeks to provide an investment return related to the performance of any MSCI index (collectively, “Index Linked Investments”). MSCI makes no assurance that any Index Linked Investments will accurately track index performance or provide positive investment returns. MSCI Inc. is not an investment adviser or fiduciary and MSCI makes no representation regarding the advisability of investing in any Index Linked Investments.


Index returns do not represent the results of actual trading of investible assets/securities. MSCI maintains and calculates indexes, but does not manage actual assets. Index returns do not reflect payment of any sales charges or fees an investor may pay to purchase the securities underlying the index or Index Linked Investments. The imposition of these fees and charges would cause the performance of an Index Linked Investment to be different than the MSCI index performance.


The Information may contain back tested data. Back-tested performance is not actual performance, but is hypothetical. There are frequently material differences between back tested performance results and actual results subsequently achieved by any investment strategy.


Constituents of MSCI equity indexes are listed companies, which are included in or excluded from the indexes according to the application of the relevant index methodologies. Accordingly, constituents in MSCI equity indexes may include MSCI Inc., clients of MSCI or suppliers to MSCI. Inclusion of a security within an MSCI index is not a recommendation by MSCI to buy, sell, or hold such security, nor is it considered to be investment advice.


Data and information produced by various affiliates of MSCI Inc., including MSCI ESG Research Inc. and Barra LLC, may be used in calculating certain MSCI equity indexes. More information can be found in the relevant standard equity index methodologies on www.msci.com.


MSCI receives compensation in connection with licensing its indexes to third parties. MSCI Inc.’s revenue includes fees based on assets in investment products linked to MSCI equity indexes. Information can be found in MSCI’s company filings on the Investor Relations section of www.msci.com.


MSCI ESG Research Inc. is a Registered Investment Adviser under the Investment Advisers Act of 1940 and a subsidiary of MSCI Inc. Except with respect to any applicable products or services from MSCI ESG Research, neither MSCI nor any of its products or services recommends, endorses, approves or otherwise expresses any opinion regarding any issuer, securities, financial products or instruments or trading strategies and neither MSCI nor any of its products or services is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Issuers mentioned or included in any MSCI ESG Research materials may include MSCI Inc., clients of MSCI or suppliers to MSCI, and may also purchase research or other products or services from MSCI ESG Research. MSCI ESG Research materials, including materials utilized in any MSCI ESG Indexes or other products, have not been submitted to, nor received approval from, the United States Securities and Exchange Commission or any other regulatory body.


Any use of or access to products, services or information of MSCI requires a license from MSCI. MSCI, Barra, RiskMetrics, IPD, FEA, InvestorForce, and other MSCI brands and product names are the trademarks, service marks, or registered trademarks of MSCI or its subsidiaries in the United States and other jurisdictions. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and Standard & Poor’s. “Global Industry Classification Standard (GICS)” is a service mark of MSCI and Standard & Poor’s.



53 billion illegal cigarettes consumed in the European Union last year

Business Wire India

53 billion illegal cigarettes were consumed in the European Union (EU) in 2015, which exceeds the legal market volume of Spain1, according to a new report published today by KPMG. Accounting for 1 in every 10 cigarettes consumed, this criminal activity costs EU governments up to EUR 11.3 billion in lost tax revenues.


This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160608005602/en/


This annual study investigates the levels and drivers of counterfeit, contraband and Illicit Whites2 in the 28 EU countries, as well as Switzerland and Norway.


While the illegal cigarette market in the EU accounts for around 10% of total consumption, this volume has declined marginally compared to 2014 as a result of several factors including increased activities to fight illegal trade and improved economic conditions.


The industry believes their strict supply chain controls and shared intelligence, combined with authorities’ law enforcement, has resulted in a decline of around 20% in the illegal flow originating from within the EU. This means that 88% of illegal cigarettes now come from non-EU countries.


A key trend identified in the KPMG report is the growing proportion of counterfeit and Illicit White brand flows compared to previous years. Illicit Whites accounted for over one third of all illegal cigarettes, whilst counterfeit grew to 4.7 billion cigarettes. The largest portion of Illicit Whites – 5.3 billion cigarettes – were in packs with Belarusian labelling.


The industry believes the changing mix of source countries and the increasing number of Illicit White brands demonstrates the adaptability of criminals who profit from the illegal tobacco market.


Key insights of the report:

  • Total illegal cigarette volumes accounted for 9.8% of all cigarettes consumed in the EU in 2015, representing 53 billion cigarettes;
  • Poland and France recorded the highest volumes of illegal cigarettes;
  • 88% of illegal cigarettes were coming from non-EU contraband and counterfeit;
  • Illicit Whites represent over one third of the illegal cigarettes consumed in the EU, 28% of which were cigarettes in packs with Belarusian labelling;
  • 1.3 billion Illicit White cigarettes are thought to originate from the Jebel Ali Free Trade Zone in the United Arab Emirates;
  • Belarus is the largest source country for Illicit Whites;
  • Counterfeit increased by 28% to 4.7 billion cigarettes;
  • Seizures of illegal cigarettes with the support of the EU Anti-Fraud Office (OLAF) doubled in 2015. In excess of 0.6 billion cigarettes were seized, compared with 0.3 billion in 2014;
  • If the illegal volume in the EU had been consumed legally, an additional tax revenue of EUR 11.3 billion would have been raised.

Charlie Simpson, lead partner of the study at KPMG, commented: “Overall, levels of illicit cigarette consumption in the EU declined slightly during 2015. Despite this, illicit tobacco continues to represent a sizeable proportion of overall cigarette consumption. It’s clear that the ever-evolving illegal tobacco market continues to affect countries throughout the EU. This year our research found that counterfeit and Illicit White brand flows made up a larger proportion of illicit consumption compared to previous years, which seems to demonstrate the flexibility of illicit cigarette flows.”


The industry believes the 2015 report results indicate that the increased joint efforts of governments, law enforcement agencies, manufacturers, and retailers contribute to efficiently addressing the illegal cigarette flows in EU. As criminals increasingly concentrate on illegal products such as Illicit Whites and shift to new source countries outside the EU, it is clear that efforts to fight illegal trade must be maintained in order to disrupt criminal networks.


British American Tobacco (BAT), Imperial Tobacco (Imperial), Japan Tobacco International (JTI) and Philip Morris International (PMI) remain committed to working together with authorities across the world and continue to invest in combating this problem.


The 2015 KPMG study on the illicit cigarette market in the EU, Switzerland and Norway is available on KPMG’s website: www.kpmg.com/uk/projectsun




KPMG Study on the illicit cigarette consumption in the EU:


KPMG has conducted this study every year since 2006. Since 2013, the study has been commissioned by all four major tobacco manufacturers –BAT, Imperial, JTI and PMI.


The study is the only comprehensive annual measurement of the black market for cigarettes in the EU. Access to a wider set of data sources, as well as methodology improvements in line with feedback received from external stakeholders, have allowed KPMG to further refine the completeness of the analysis over the years. The study’s methodology is presented in detail in the report.


The OECD considers the methodology of KPMG LLP the “most authoritative assessment of the level of counterfeit and contraband cigarettes” in the EU. KPMG LLP recognises the wider public policy context within which governments decide regulatory and fiscal changes for the tobacco industry, and that the analysis in this report only considers one aspect. KPMG LLP expresses herein no view, nor makes any recommendation, in relation to future policy for the industry in this regard.


About British American Tobacco plc:


British American Tobacco is a global tobacco Group with brands sold in more than 200 markets.


It employs more than 57,000 people worldwide and has over 200 brands in its portfolio, with its cigarettes chosen by one in eight of the world’s one billion smokers. Alongside offering tobacco products, British American Tobacco is committed to offering safer nicotine alternatives to adult smokers. As such, it was the first tobacco company to launch an e-cigarette in the UK. www.bat.com


About Imperial Tobacco:


Imperial Tobacco is part of Imperial Brands PLC, the UK FTSE100 parent company of a dynamic international business with around 34,000 employees. Brands sold in markets worldwide by Imperial Tobacco include Davidoff, Gauloises Blondes, West, JPS and Rizla. For more information see www.imperialbrandsplc.com


About JTI:


JTI, a member of the Japan Tobacco Group of Companies, is a leading international tobacco manufacturer. It markets global brands such as Winston, Camel, Mevius and LD. JTI is a global player in the e-cigarette market with E-Lites and Logic, and has been present in the heated tobacco sector with Ploom since 2011. Headquartered in Geneva, Switzerland, and with operations in more than 120 countries, JTI employs around 26,000 employees worldwide. Its core revenue in the fiscal year ended December 31, 2015, was USD 10.3 billion. For more information, visit www.jti.com.


About Philip Morris International Inc. (“PMI”):


PMI is the world’s leading international tobacco company, with six of the world's top 15 international brands and products sold in more than 180 markets. In addition to the manufacture and sale of cigarettes, including Marlboro, the number one global cigarette brand, and other tobacco products, PMI is engaged in the development and commercialization of Reduced-Risk Products (“RRPs”). RRPs is the term PMI uses to refer to products with the potential to reduce individual risk and population harm in comparison to smoking cigarettes. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and industry-leading scientific substantiation, PMI aims to provide an RRP portfolio that meets a broad spectrum of adult smoker preferences and rigorous regulatory requirements. For more information, see www.pmi.com and www.pmiscience.com.


1 Legal domestic sales volume in Spain is 47 billion cigarettes according to the Tobacco Commissioner.


2 ‘Illicit Whites’ – Cigarettes that are usually manufactured legally in one country/market but which the evidence suggests have been smuggled across borders during their transit to the destination market under review where they have limited or no legal distribution and are sold without payment of tax.




YASH Technologies Achieves ISO 27001:2013 Information Security Management System Certification (ISMS)

Business Wire India
YASH Technologies™, a leading technology services and outsourcing partner for global companies, today announced it has achieved the ISO 27001:2013 Information Security Management System (ISMS) Standard for IT consulting and managed services, including software development, maintenance, and testing.  Upgradation from ISO 27001: 2005 to ISO 27001:2013 is a reaffirmation of YASH’s continued compliance to the highest standards of information security management, and commitment to remaining current and relevant to new age risks and vulnerabilities.
The ISO 27001 ISMS Standards is a process approach established and updated by the International Organization for Standardization (ISO), the world’s largest developer of international standards. The ISO 27001:2013 ISMS Standard specifies the requirements for establishing, implementing, maintaining, and continually improving an information security management system (ISMS) for any organization, regardless of type or size.
“Increasing IT threats make it even more crucial for organizations to remain compliant with the latest security guidelines and avert risk. The latest certification acknowledges YASH Technologies’ continuous efforts to ensure customers with the highest level of information security, seamless business continuity, and operational excellence,” said Murali Jothilingam, vice president of IMS, YASH Technologies.  “We are delighted to achieve this international accreditation and would like to congratulate our team members for their sheer hard work and dedication, and also our customers and partners for their constant support and faith in YASH,”  he added. 
ISO is a network of the national standards institutes for 162 countries and created the standard to set international requirements for quality management systems.

About YASH Technologies
YASH Technologies focuses on customer success. As a leading technology services and outsourcing partner for large and fast growing global customers, the company leverages technology and flexible business models to drive innovation and value throughout its customer’s enterprise. YASH customer centric engagement & delivery framework integrates specialized domain and consulting capabilities with proprietary methodologies and solution offerings to provision application, infrastructure and end user focused Right-Sourcing services. YASH is a SEI CMMI (Level 3) and an ISO 9001:2013 certified company with U.S. and India headquarters and regional sales and development offices globally with customers spread across 6 continents. For more information, please visit www.YASH.com or email info@YASH.com.

At DRUPA, Comiflex Shakes Hands with Uflex to Make In India

Business Wire India
Italian firm Comiflex SRL has shaken hands with India’s largest global flexible packaging solution company Uflex Limited confirming its intent to manufacture Gearless C.I. Flexo Printing Machines under a Technology Transfer Agreement with the latter. This happened at DRUPA where Uflex is currently exhibiting.
The memorandum of understanding has already been signed between Mr. Gianfranco Nespoli, Owner of Comiflex SRL and Mr. Ajay Tandon, President & CEO, Engineering Business, Uflex Limited. Uflex will market and sell these machines across the world.
With 50 years of enriching experience to his credit, Mr. Gianfranco Nespoli, is a renowned exponent in the field of designing and producing high quality C.I. Flexo Machines. Mr. Nespoli is one of the founding members of Flexotecnica that was founded in 1979 in Galganano for manufacturing flexo printing presses for roll to roll printing on films and paper for packaging applications.
Expressing his pleasure, Mr. Ashok Chaturvedi, Chairman and Managing Director, Uflex Limited, who is currently attending DRUPA said “We will be manufacturing Gearless C.I. Flexo Printing Machines in collaboration with Comiflex SRL at our Engineering Plant in India. I am glad that Uflex has partnered with one of the sharpest brains of the C.I. Flexo printing machine technology. Innovation to create value added differentiation is the guiding principle at Uflex and our engagement with Mr. Gianfranco Nespoli’s Comiflex SRL testifies it”. “This tie-up furthers the ethos and spirit of my Government’s flagship scheme Make in India,” added Mr. Chaturvedi.

Uflex is in Hall No. 15 at Stand No. C 51 from May 31 to June 10, 2016

About Uflex
Uflex is India’s largest end-to-end flexible packaging company and an emerging global player. Since its inception back in 1983, Uflex has grown from strength to strength to evolve as a truly Indian Multinational with consumers spread across the world. Uflex today has state-of-the-art packaging facilities at multiple locations in India with installed capacity of around 100,000 TPA and has packaging film manufacturing facilities in India, UAE, Mexico Egypt, Poland and USA with cumulative installed capacity in excess of 337,000 TPA.
All Uflex plants are accredited with ISO 9001, 14001, HACCP & BRC certifications. Uflex caters to markets spanning across the globe in over 140 countries like USA, Canada, South American countries, UK and other European Countries, Russia, South Africa, CIS, Asian and African nations. Integrated within its core business profile are allied businesses like Engineering, Cylinders, Holography and Chemicals which further give Uflex a superior edge above competition.
Uflex Limited is also a part of the D&B Global Database and winner of various prestigious national and international awards for its products’ excellence. Uflex offers technologically superior packaging solutions for a wide variety of products such as snack foods, candy and confectionery, sugar, rice & other cereals, beverages, tea & coffee, dessert mixes, noodles, wheat flour, soaps and detergents, shampoos & conditioners, vegetable oil, spices, marinates & pastes, cheese & dairy products, frozen food, sea food, meat, anti-fog, pet food, pharmaceuticals, contraceptives, garden fertilizers and plant nutrients, motor oil and lubricants, automotive and engineering components etc.
Some of Uflex’s clients on the global turf include P&G, PepsiCo; Tata Global; Mondelez, L’ Oreal, Britannia, Haldiram’s, Amul, Kimberly-Clark, Ferro Rocher, Perfetti, GSK, Nestle, Agrotech Foods Coca-Cola, Wrigley, Johnson & Johnson among others.

Photo Caption: L-R: Ajay Tandon, Gianfranco Nespoli, Ashok Chaturvedi

Kubota, NTT and NTT Communications to Develop ICT Solutions for Agriculture and Water Infrastructure

Business Wire India

Kubota Corporation, Nippon Telegraph and Telephone Corporation (NTT) and NTT Communications Corporation (NTT Com) announced today an agreement, effective immediately, to combine Kubota’s infrastructure solutions for agriculture and water management, NTT’s research and development capabilities, and ICT services from NTT Com and other NTT Group companies to enhance agricultural competitiveness and upgrade living standards.


Research and development will focus on creating agricultural solutions that enable farms to better visualize and manage their agricultural businesses, including through enhanced efficiency and automation, and water solutions that enable extra-efficient monitoring and management of water resources.


The solutions will variously incorporate advanced agricultural machinery, farm-support systems and water infrastructure from Kubota; global cloud and security services from NTT Com; wireless technologies, weather and map information and other ICT services from the NTT Group; artificial intelligence, including the corevo™ failure-detection system leveraging AI and IoT technologies developed by NTT for the Internet of Things and big data.


Kubota is accelerating its global businesses in the fields including agriculture machinery and water management under a business restructuring strategy named Global Major Brand Kubota. The company is strengthening its development of agricultural technologies and solutions, such as the Kubota Smart Agri System that leverages ICT for enhanced agricultural management.


NTT is enhancing its comprehensive capabilities as a value partner for customers by working with partners to develop ICT-based “Co-Innovation” initiatives. One of its new strategic business fields is agriculture, where it is partnering with other companies, including through the NTT Group Crossing Project.


NTT Com is helping customers with the digital transformations of their businesses. Specifically, NTT Com is optimizing their ICT environments with innovative solutions that incorporate global seamless services for clouds, colocation, networks, applications, security and managed ICT.


About Kubota Corporation


Kubota Corporation (TSE:6326) is one of Japan’s leading manufacturers of a comprehensive range of machinery and other industrial and consumer products. Since 1890, Kubota Corporation has offered various products including farm equipment, engines, construction machinery, electronic equipped machinery, pipe-related products, environment-related products, and social infrastructure-related products to contribute to improve human lives and society. With broad product lineup and its unique comprehensive strength, Kubota Corporation presents in more than 110 countries and strives to solve the worldwide problems related to food, water and the environment, which are indispensable for human beings.
Please visit http://www.kubota-global.net/index.html for the latest news and more information.


About Nippon Telegraph and Telephone Corporation


NTT Group delivers advanced technology and innovative solutions in networking, software communications, and cloud computing that help transform businesses, governments and societies around the world.
NTT Group will deliver convenient, enriched and reliable services to support customers as a “Value Partner” that its customers will continue to select. Today, 80% of Fortune 100 companies rely on NTT Group as their business partner. NTT Group generates over $105 billion in annual revenues, has over 233 data centers and employs more than 240,000 professionals working in 88 countries.
www.ntt.co.jp | NTT Group@Twitter | NTT Group@Facebook |NTTGroup@Instagram | NTT Group@LinkedIn


About NTT Communications Corporation


NTT Communications provides consultancy, architecture, security and cloud services to optimize the information and communications technology (ICT) environments of enterprises. These offerings are backed by the company’s worldwide infrastructure, including the leading global tier-1 IP network, the Arcstar Universal One™ VPN network reaching 196 countries/regions, and 140 secure data centers worldwide. NTT Communications’ solutions leverage the global resources of NTT Group companies including Dimension Data, NTT DOCOMO and NTT DATA.
www.ntt.com | Twitter@NTT Com | Facebook@NTT Com | LinkedIn@NTT Com






Business Wire India

AstraZeneca announced clinical and safety data for Tagrisso (osimertinib) in patients with leptomeningeal (LM) disease, a complication of epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC),1 where cancer cells spread to the cerebrospinal fluid (CSF). LM is a devastating disease associated with advanced lung cancer.


The updated BLOOM Phase I trial results, presented at the American Society of Clinical Oncology (ASCO) annual meeting, showed that irrespective of T790M status of patients, osimertinib led to a change in MRI signal intensity indicative of a reduction in central nervous system (CNS) lesions. 1


Data from 21 patients treated with osimertinib 160mg once daily showed intracranial radiological improvement in seven patients, neurological function improvement in five patients, and clearance of tumour cells from the CSF at two consecutive visits in two patients.1 None of the 21 patients treated with osimertinib received concomitant radiotherapy or intrathecal chemotherapy. Fifteen patients remained on treatment at data cut-off (10 March 2016), of whom seven had been on treatment for more than nine months.1


Further data from the BLOOM study showed that osimertinibcrossed the blood-brain barrier. In six of nine patients, a greater than 50% decrease in EGFR mutation level was observed in the CSF up to cycle 9, day 1 of treatment, with a sustained reduction observed in five. These results support previously reported preclinical data demonstrating that osimertinib crosses the blood-brain barrier.2


Dr James CH Yang, from the National Taiwan University Hospital and National Taiwan University Cancer Centre, Taipei, said: “Leptomeningeal disease carries a devastating prognosis, so the safety, tolerability and activity profile seen with osimertinib is encouraging. In the BLOOM study, we saw a decrease in central nervous system lesions in patients with leptomeningeal disease, with accompanying neurological improvement. The results build on previous findings with osimertinib in preclinical and clinical studies and provide evidence of the potential of osimertinib in difficult-to-treat patients who have central nervous system metastases.”


In leptomeningeal disease, cancer cells spread to the membranes surrounding the brain and spinal cord. The disease is currently treated with systemic or intrathecal chemotherapy, whole-brain radiation therapy or EGFR tyrosine kinase inhibitors (TKIs), with median overall survival of 4.5-11 months.3,4 However, most currently-available EGFR-TKIs have limited ability to cross the blood-brain barrier to effectively treat or prevent brain metastases.5-7


Osimertinib 160mg was associated with a manageable tolerability profile over treatment periods up to 11 months. The most common adverse events reported by patients were diarrhoea (58% overall; 5% ≥Grade 3), nausea (48% overall; 0% ≥Grade 3) and rash (43% overall; 0% ≥Grade 3). There were no reported cases of interstitial lung disease, hyperglycaemia or QT prolongation.


Osimertinibrecently received accelerated approval as the first indicated treatment for patients with EGFR T790M mutation-positive locally advanced/metastatic NSCLC in the US, EU, Japan and Israel. Osimertinib is also approved in South Korea in the same indication.


AstraZeneca is committed to exploring the full potential of osimertinib in patients with lung cancer, including adjuvant and locally advanced/metastatic first-line EGFRm settings, in patients with and without brain metastases, and in those with leptomeningeal disease.8


– ENDS –




About Non-Small Cell Lung Cancer (NSCLC)


Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-third of all cancer deaths and more than breast, prostate and colorectal cancers combined.9 Patients who have the EGFRm form of NSCLC, which occurs in 10-15% of NSCLC patients in Europe10 and 30-40% of NSCLC patients in Asia,11 are particularly sensitive to treatment with currently available EGFR-TKIs, which block the cell signalling pathways that drive the growth of tumour cells.12 However, tumours almost always develop resistance to treatment, leading to disease progression.13 In approximately two-thirds of patients treated with approved EGFR-TKIs such as gefitinib and erlotinib, this resistance is caused by the secondary mutation, T790M.13


About leptomeningeal disease


In leptomeningeal disease, cancer cells spread to the membranes surrounding the brain and spinal cord. It is a complication that affects 3-5% of patients with NSCLC14, and 9% of those with EGFRm NSCLC.15 Treatment is challenging due to poor penetration of the blood-brain barrier by most EGFR-TKI therapies, making it difficult for drugs to reach the brain and spinal cord. 5-7 Average survival in patients with EGFRm NSCLC and leptomeningeal disease is 4.5 to 11 months.3-4 In a recently reported “real-world” retrospective analysis of patients with EGFRm NSCLC treated with EGFR-TKIs, overall survival was approximately 30 months.16


About osimertinib


Osimertinib 80mg once-daily tablet is the first medicine indicated for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. Non-clinical in vitro studies have demonstrated that osimertinibhas high potency and inhibitory activity against mutant EGFR phosphorylation across the range of clinically relevant EGFR and T790M mutant NSCLC cell lines with significantly less activity against EGFR in wild-type cell lines.17


Osimertinib is being compared with platinum-based doublet chemotherapy in the confirmatory AURA3 Phase III study in patients with EGFR T790M mutation-positive, locally advanced or metastatic NSCLC who have progressed after EGFR-TKI therapy.18 It is also being investigated in the adjuvant and metastatic first-line settings,19,20 including in patients with and without brain metastases, in leptomeningeal disease,8 and in combination treatment.21


About AstraZeneca in Oncology


AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least 6 new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s six Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.


By harnessing the power of four scientific platforms — immuno-oncology, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates — and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.


About AstraZeneca


AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology – as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com




1Yang JCH, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a Phase I study. Abstract 9002 [Oral Presentation]. Presented at the annual meeting of the American Society of Clinical Oncology, 3-7 June 2016, Chicago, USA.


Ballard P, et al. Preclinical activity of AZD9291 in EGFR-mutant NSCLC brain metastases. Presented at the World Congress on Lung Cancer, 6-9 September 2015. Denver, Colorado, USA.


Liao BC et alEpidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. J Thorac Oncol. 2015;10(12):1754-61.


4 Umemura S et alClinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study GroupLung Cancer. 2012;77(1):134-9.


5 European Medicines Agency CHMP assessment report for Giotrif. 2013.


De Vries NA et alRestricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs. 2012;30(2):443-9.


Zhao J et alCerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer. 2013 Mar;14(2):188-93.


National Institutes of Health. Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM). Available at: https://clinicaltrials.gov/ct2/show/NCT02228369?term=AZD9291+brain+met&rank=1. Accessed May 2016.


GLOBOCAN (2012). Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed May 2016.


10 Szumera-Ciećkiewicz A, et al. EGFR mutation testing on cytological and histological samples in non-small cell lung cancer: a Polish, single institution study and systematic review of European incidenceInt J Clin Exp Pathol. 2013;6:2800-12.


11 Ellison G, et al. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samplesJ Clin Pathol. 2013;66:79-89.


12 Langer CJ, et al. Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non-Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer? Journal of Clinical Oncology. 2013;31(27);3303-3305.


13 Yu HA, et al. Analysis of Tumour Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung CancerClin Cancer Research:2013:19(8):2240-2246.


14 Chamberlain MC, et alCarcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy.Arch Neurol. 1998;55(4):506-12.


15 Kuiper JL, et al. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysisLung Cancer. 2015;89(3):255-61.


16 Inoue A, et alCharacteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Jpn J Clin Oncol. 2016;pii: hyw014 [Epub ahead of print].


17 Cross DAE, et al. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung CancerCancer Discov. 2014;4:1046-61.


18 National Institutes of Health. AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (AURA3). Available at: https://clinicaltrials.gov/ct2/show/NCT02151981?term=AURA3&rank=1. Accessed May 2016.


19 National Institutes of Health. AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA). Available at:https://www.clinicaltrials.gov/ct2/show/NCT02511106?term=AZD9291+Versus+Placebo+in+Patients&rank=1. Accessed May 2016.


20 National Institutes of Health. AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA). Available at https://clinicaltrials.gov/ct2/show/NCT02296125?term=FLAURA&rank=1. Accessed May 2016.


21 National Institutes of Health. AZD9291 in Combination With Ascending Doses of Novel Therapeutics. Available at:https://www.clinicaltrials.gov/ct2/show/NCT02143466?term=azd9291&rank=1. Accessed May 2016.


– ENDS –